Peyronie's Disease: Causes, Diagnosis, and Treatment Options

Peyronie's disease is a connective tissue disorder of the penis characterized by fibrous plaque formation within the tunica albuginea, producing penile curvature, pain, deformity, and frequently erectile dysfunction. It is not rare — prevalence estimates range from 3–9% of men — but it is commonly undertreated because men delay seeking evaluation due to embarrassment. [^schwarzer2001]

Pathophysiology

The tunica albuginea is the multilayered fibrous sheath surrounding the corpora cavernosa. Under normal conditions, it is elastic and accommodates erection-induced expansion symmetrically. Peyronie's disease disrupts this by depositing inelastic fibrous plaque within the tunica.

The initiating event in most cases is trauma to the penis during intercourse — typically buckling or bending during attempted penetration or during intercourse when the penis partially slips out and re-enters at an angle. This causes microtears in the tunica. In most men, this heals without consequence. In men with genetic predisposition (HLA associations, TGF-β1 pathway variants), the healing response is dysregulated. [^shindel2012]

TGF-β1 (transforming growth factor beta-1) is the key mediator: microtears trigger TGF-β1 release, which upregulates fibroblast activity, collagen production (particularly type III collagen), and suppresses collagenase activity. The result is progressive fibrosis — collagen deposits in the healing zone that are replaced by calcification in chronic cases rather than normal elastic tissue. [^shindel2012]

The resulting plaque is inelastic. During erection, the affected portion of the tunica does not expand normally — the penis bends toward the plaque. A dorsal plaque (most common) produces upward curvature; lateral plaques produce lateral deviation; ventral plaques produce downward curvature. Complex plaques produce rotational or hourglass deformities.

Natural History: Two Phases

Acute Phase (6–18 months from onset)

Characterized by:

• Active penile pain, most prominent during erection
• Progressive change in curvature as plaque evolves
• Plaque palpable but soft

During this phase, the disease is active and unstable. Surgical correction is not indicated because curvature continues to change. Non-surgical intervention is most plausible during this window (when the plaque is remodeling rather than calcified).

Spontaneous partial improvement occurs in approximately 12–13% of men during the acute phase — most commonly in pain, which typically resolves with or without treatment. [^mulhall2004]

Chronic Phase (after stabilization)

Characterized by:

• Pain resolution in most men
• Stable curvature (no change over 3–6 months)
• Plaque may calcify (palpable as hard nodule, detectable on ultrasound)
• Deformity is fixed — without intervention, it does not resolve

Most men require surgical correction for significant deformity affecting sexual function, undertaken once the disease has stabilized.

Symptoms and Assessment

Curvature

Measured at maximum erection using a goniometer or photograph. The degree and direction are documented. Curvature under 30° typically does not impair intercourse; 30–60° is variable; greater than 60° usually prevents intercourse.

Erectile Dysfunction

Peyronie's disease-associated ED is common (25–50% of patients) and multifactorial: [^shindel2012]

• Mechanical (curvature prevents comfortable penetration)
• Vascular (plaque can impair corporal veno-occlusive mechanism)
• Psychological (anxiety, body image, relationship distress)
• PDE5 inhibitor non-response is higher in Peyronie's than in primary vascular ED

Pain

Present in approximately 35–70% of men in acute phase; resolves in most by chronic phase without treatment.

Psychological Impact

Peyronie's disease produces substantial psychological distress disproportionate to the physical findings. The Peyronie's Disease Questionnaire (PDQ) documents depression, relationship anxiety, and sexual self-image disruption that is clinically significant in most patients. [^rosen2008] Psychological impact should be directly assessed and addressed.

Diagnosis

Diagnosis is clinical — history and physical examination. Imaging is adjunctive.

Physical examination: Penis examined flaccid and (ideally) photographed during self-administered erection (sildenafil-assisted photograph at home, submitted to clinician). The location, size, and consistency of the plaque are documented.

Penile ultrasound with vasoactive injection: Color Doppler ultrasound after intracavernosal injection of vasoactive agent provides: plaque location/extent, presence of calcification, and hemodynamic assessment (detecting co-existing venous leak or arterial insufficiency). Essential before surgical planning.

Penile X-ray: Simple radiograph detects calcification (seen in 20–30% of chronic cases) but provides limited anatomical detail.

Non-Surgical Treatment (Acute Phase)

Non-surgical treatments are most appropriate during the acute phase, when the plaque is actively remodeling.

Collagenase Clostridium Histolyticum (CCH / Xiaflex)

The only FDA-approved pharmacological treatment for Peyronie's disease (approved 2013). CCH is a bacterial collagenase enzyme that degrades collagen types I and III — the predominant collagen types in Peyronie's plaques.

IMPRESS trials (2013): Two large phase 3 RCTs randomized 832 men to CCH injection versus placebo. Results: [^gelbard2013]

• Mean curvature reduction: 17° in CCH group vs 9° in placebo group (absolute reduction of ~34° vs ~20° from baseline)
• Percentage of men achieving ≥20% curvature reduction: 71% CCH vs 52% placebo
• Bother score improvement: significant vs placebo
• Side effects: localized penile swelling, bruising, and pain in most patients; penile fracture (corporal rupture) occurred in approximately 0.9%

Protocol: Intralesional injection into the plaque, followed 24–72 hours later by penile modeling (gentle manual bending opposite to the curvature direction). Cycles repeated up to 4 times at 6-week intervals.

Suitable candidates: Men with stable disease (curvature not changing), curvature 30–90°, palpable plaque without calcification (calcified plaques do not respond), curvature direction where injection is technically feasible.

Penile Traction Therapy

Mechanical stretching of the penis using a traction device (vacuum or spring-loaded) applies longitudinal force to the penis, targeting plaque remodeling and preventing fibrotic contracture.

Evidence from uncontrolled studies shows curvature reduction of 10–25° with 3–6 months of use (>3 hours/day). [^bella2007] Not a primary treatment but valuable:

• As adjunct to CCH (combination shows greater curvature reduction than CCH alone)
• In men who cannot receive CCH (contraindications: blood thinners, penile anatomy precluding injection)
• For length preservation (Peyronie's commonly shortens the penis on the affected side)

Intralesional Verapamil

Calcium channel blocker thought to inhibit fibroblast activity and TGF-β1 signaling. Evidence from small trials shows modest curvature reduction (12–15°) and pain improvement. Less established than CCH. Used in some centers for men not CCH candidates.

Interventions Without Meaningful Evidence

Oral vitamin E, colchicine, and tamoxifen are commonly used in some regions but lack convincing RCT evidence and are not recommended by major urology guidelines (AUA, EAU).

Surgical Treatment (Chronic Phase)

Surgery is indicated for stable Peyronie's disease with curvature that impairs sexual function and does not respond to non-surgical management.

Plication Procedures (Nesbit Procedure and Variants)

Sutures placed on the convex side of the curvature shorten the longer side to match the plaque-shortened side, straightening the penis. [^nesbit1965]

Suitable candidates: Adequate penile length, curvature <60°, no significant ED.

Outcomes: High success rate for curvature correction (75–90%). Predictable shortening of 1–3 cm (correcting 10° per cm). ED risk is low. Sensory changes in a minority.

Not suitable for: Men with already short penis (further shortening is unacceptable), curvature >60° (requires more shortening), or calcified plaques.

Incision/Excision and Grafting

Plaque is incised or excised and the defect covered with a graft (synthetic or autologous). Maintains or restores penile length.

Suitable candidates: Curvature >60°, significant deformity, adequate erectile function pre-operatively.

Outcomes: Better curvature correction for complex cases, better length preservation. Higher ED risk (15–25%) due to neurovascular manipulation. Graft-site complications possible.

Penile Prosthesis Implantation

Inflatable penile prosthesis is the definitive treatment when Peyronie's disease co-exists with significant ED. Prosthesis straightens the penis mechanically (intraoperative modeling and, if needed, plaque incision and grafting combined with implant). [^levine2015]

Patient satisfaction with inflatable prosthesis in Peyronie's disease is 80–85% at 5 years — the highest patient satisfaction outcome in Peyronie's treatment among men with co-existing ED.

What Not to Expect

• Spontaneous full resolution is rare (<5% of cases). Most men who improve do so partially and in the acute phase only.
• Non-surgical treatments (CCH, traction) correct curvature partially, not completely. Realistic expectation: 30–50% curvature reduction, not straightening.
• Treatment during acute phase cannot predict final stable curvature — this is why surgery is delayed until stabilization.

When to Seek Evaluation

Men should not wait with Peyronie's disease. Early evaluation during the acute phase allows:

• Treatment during the remodeling window (most responsive period for CCH)
• Psychological support during the high-distress onset period
• Documentation of disease course for surgical planning

Any man with new onset penile curvature, palpable penile nodule, or penile pain during erection should be evaluated by a urologist — ideally one specializing in sexual medicine.

Bottom Line

Peyronie's disease is fibrous plaque formation in the tunica albuginea producing penile curvature, pain, and erectile dysfunction. Two phases require different management: acute (active, remodeling — appropriate for CCH or traction) and chronic (stable — appropriate for surgery if function is impaired). Collagenase clostridium histolyticum (Xiaflex) is the only FDA-approved drug, producing approximately 17° curvature reduction in clinical trials. Plication surgery for mild-moderate curvature and penile prosthesis for severe cases with co-existing ED produce the most reliable outcomes. Early evaluation during the acute phase is strongly recommended.